Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990807 | 0.84 | MAPT (0.62) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL15569388 | 0.84 | MAPT (0.62) | MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2061231 | 0.83 | LMNA (0.55) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL8356885 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL6960026 | 0.82 | ALDH1A1 (0.53) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL8356716 | 0.81 | MAPT (0.51) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL4172495 | 0.81 | MAPT (0.58) | MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL25697926 | 0.81 | MAPT (0.58) | MAPTALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL9829974 | 0.79 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL5071255 | 0.79 | MAPT (0.57) | MAPTALDH1A1KDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2408745-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010106081-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-23 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | MAPT 4727/4885ALDH1A1 902/4885KDM4E 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.